Citations

Mayo Clinic

Showing 10 of 108522 citations.

Femoral Nerve Block Is Associated With Persistent Strength Deficits at 6 Months After Anterior Cruciate Ligament Reconstruction in Pediatric and Adolescent Patients
Luo, T. David , Ashraf, Ali , Dahm, Diane L., McIntosh, Amy L. , Stuart, Michael J.

The American Journal of Sports Medicine | December 2, 2014 | Volume: 43 | Issue: 2 | Pages: 331-336

10.1177/0363546514559823 | PMID 25466410 Get It

Background: Femoral nerve block (FNB) has become a popular method of postoperative analgesia for anterior cruciate ligament (ACL) reconstruction in pediatric and adolescent patients. Successful rehabilitation after surgery involves return of quadriceps and hamstring strength. Purpose: To compare knee strength and function 6 months after ACL reconstruction in pediatric and adolescent patients who received FNB versus patients with no nerve block. Study Design: Cohort study; Level of evidence, 3. Methods: Patients 18 years or younger who underwent primary ACL reconstruction between 2000 and 2010 at a single institution were identified. If the patient was skeletally immature, a transphyseal ACL reconstruction was performed. Of these patients, 68% underwent reconstruction with a patellar tendon autograft, and in 32% of patients a hamstring autograft was utilized. There were 124 patients who met the study inclusion criteria, including 62 in the FNB group (31 males, 31 females) and 62 patients in the control group (25 males, 37 females). All study patients participated in a comprehensive rehabilitation program that included isokinetic strength and functional testing at 6 months postoperatively. Results: Univariate analysis showed a significantly higher deficit at 6 months in the FNB group with respect to fast isokinetic extension strength (17.6% vs 11.2%; P = .01) as well as fast (9.9% vs 5.7%; P = .04) and slow (13.0% vs 8.5%; P = .03) isokinetic flexion strength. There was no difference in slow isokinetic extension strength deficit between the 2 groups (FNB, 22.3% vs control, 18.7%; P = .20). With respect to function, there were no differences in deficit for vertical jump (FNB, 9.4% vs control, 11.3%; P = .30), single hop (7.6% vs 7.5%; P = .96), or triple hop (8.0% vs 6.6%; P = .34) between the 2 groups. A significantly higher percentage of patients in the control group met functional and isokinetic criteria for return to sports at 6 months (90.2% vs 67.7%; odds ratio, 4.37; P = .002). Conclusion: Pediatric and adolescent patients treated with FNB for postoperative analgesia after ACL reconstruction had significant isokinetic deficits in knee extension and flexion strength at 6 months when compared with patients who did not receive a nerve block. Patients without a block were 4 times more likely to meet criteria for clearance to return to sports at 6 months.
A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report
Fouladi, Maryam , Perentesis, John P. , Wagner, Lars M. , Vinks, Alexander A. , Ahern, Charlotte H., Mercer, Carol A. , Krueger, Darcy A. , Houghton, Peter J. , Doyle, L. Austin, Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Thomas, George , Chen, Helen

Clinical Cancer Research | December 2, 2014 | Volume: 21 | Issue: 7 | Pages: 1558-1565

10.1158/1078-0432.ccr-14-0595 | PMID 25467181 Get It

Abstract Purpose: To determine the MTD, dose-limiting toxicities (DLT), pharmacokinetics, and biologic effects of cixutumumab administered in combination with temsirolimus to children with refractory solid tumors. Experimental Design: Cixutumumab and temsirolimus were administered intravenously once every 7 days in 28-day cycles. Pharmacokinetic and biology studies, including assessment of mTOR downstream targets in peripheral blood mononuclear cells, were performed during the first cycle. Results: Thirty-nine patients, median age 11.8 years (range, 1–21.5), with recurrent solid or central nervous system tumors were enrolled, of whom 33 were fully assessable for toxicity. There were four dose levels, which included two dose reductions and a subsequent intermediated dose escalation: (i) IMC-A12 6 mg/kg, temsirolimus 15 mg/m2; (ii) IMC-A12 6 mg/kg, temsirolimus 10 mg/m2; (iii) IMC-A12 4 mg/kg, temsirolimus 8 mg/m2; and (iv) IMC-A12 6 mg/kg, temsirolimus 8 mg/m2. Mucositis was the predominant DLT. Other DLTs included hypercholesterolemia, fatigue, thrombocytopenia, and increased alanine aminotransferase. Target inhibition (decreased S6K1 and PAkt) in peripheral blood mononuclear cells was noted at all dose levels. Marked interpatient variability in temsirolimus pharmacokinetic parameters was noted. At 8 mg/m2, the median temsirolimus AUC was 2,946 ng • h/mL (range, 937–5,536) with a median sirolimus AUC of 767 ng • h/mL (range, 245–3,675). Conclusions: The recommended pediatric phase II doses for the combination of cixutumumab and temsirolimus are 6 mg/kg and 8 mg/m2, respectively. Clin Cancer Res; 21(7); 1558–65. ©2014 AACR.
The Challenges of Trigger Ablation for Ventricular Fibrillation
Asirvatham, Samuel J. , Asirvatham, Samuel J

Journal of Cardiovascular Electrophysiology | December 2, 2014 | Volume: 26 | Issue: 1 | Pages: 116-117

10.1111/jce.12593 | PMID 25454834 Get It

Medical Thoracoscopy
Skalski, Joseph H. , Maldonado, Fabien , Astoul, Philippe J.

Seminars in Respiratory and Critical Care Medicine | December 2, 2014 | Volume: 35 | Issue: 06 | Pages: 732-743

10.1055/s-0034-1395796 | PMID 25463164 Get It

Cost Comparison Between Home Telemonitoring and Usual Care of Older Adults: A Randomized Trial (Tele-ERA)
Upatising, Benjavan, Wood, Douglas L. , Kremers, Walter K. , Christ, Sharon L. , Yih, Yuehwern , Hanson, Gregory J. , Takahashi, Paul Y. , Takahashi, Paul , Kremers, Walter K

Telemedicine and e-Health | December 2, 2014 | Volume: 21 | Issue: 1 | Pages: 3-8

10.1089/tmj.2014.0021 | PMID 25453392 Get It

Sex and sex steroids: impact on the kinetics of fatty acids underlying body shape
Santosa, Sylvia , Jensen, Michael D.

Hormone Molecular Biology and Clinical Investigation | December 2, 2014 | Volume: 20 | Issue: 1 | Pages: 15-23

10.1515/hmbci-2014-0029 | PMID 25460291 Get It

Abstract Adult humans have a remarkable sexual dimorphism in body shape. Men tend to store relatively more fat in the upper body whereas women store more fat in the lower body. We do not have a complete understanding of the mechanisms underlying these differences, but we know that people who preferentially store abdominal fat are at greater risk of metabolic disease. It is also known that the changes in sex steroid concentrations during puberty and again with advancing age are accompanied by changes in body fat distribution. The objective of this review is to describe what has been learned regarding the mechanisms underlying changes in regional body fat distribution that occur as a result of changes in sex hormones and to delineate effects of sex steroids in modulating body composition.
Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays
Katzmann, Jerry A., Kohlhagen, Mindy , Kyle, Robert A. , Murray, David , Snyder, Melissa R, Dispenzieri, Angela , Willrich, Maria Alice V. , Snyder, Melissa R, Rajkumar, S. Vincent , Dispenzieri, Angela

Clinical Chemistry | December 2, 2014 | Volume: 61 | Issue: 2 | Pages: 360-367

10.1373/clinchem.2014.231985 | PMID 25451866 Get It

AbstractBACKGROUNDThe use of electrophoresis to monitor monoclonal immunoglobulins migrating in the β fraction may be difficult because of their comigration with transferrin and complement proteins.METHODSImmunoassays specific for IgGκ, IgGλ, IgAκ, IgAλ, IgMκ, and IgMλ heavy/light chain (HLC) were validated for use in the clinical laboratory. We assessed sample stability, inter- and intraassay variability, linearity, accuracy, and reference intervals for all 6 assays. We tested accuracy by verifying that the sum of the concentrations for the HLC-pairs accounted for the total immunoglobulins in each of 129 healthy sera, and that the HLC-pair ratios (rHLCs) were outside the reference interval in 97% of 518 diagnostic multiple myeloma (MM) samples.RESULTSWe assessed diagnostic samples and posttreatment sera in 32 IgG and 30 IgA patients for HLC concentrations, rHLC, and total immunoglobulins and compared these nephelometry results with serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE). In sample sets from patients with IgG MM, the sensitivity of SPEP was almost the same as for rHLC, and no additional advantage was conferred by running HLC assays. In pre- and posttreatment samples from patients with IgA MM, the SPEP, rHLC, and IFE identified clonality in 28%, 56%, and 61%, respectively. In addition, when M-spikes were quantifiable, the concentration of the involved HLC was linearly related to that of the SPEP M-spike, with a slope near 1.CONCLUSIONSThe use of IgA HLC assays for monitoring β-migrating IgA monoclonal proteins can substitute for the combination of SPEP, IFE, and total IgA quantification.
Circulating Atrial Natriuretic Peptide Genetic Association Study Identifies a Novel Gene Cluster Associated With Stroke in Whites
Pereira, Naveen L. , Tosakulwong, Nirubol , Jenkins, Gregory D. , Prodduturi, Naresh, Olson, Timothy M. , Rodeheffer, Richard J. , Redfield, Margaret M. , Weinshilboum, Richard M. , Burnett, John C. , Chai, Yubo, Scott, Christopher G. , Chai, Yubo , Weinshilboum, Richard M. , Olson, Timothy M

Circulation: Cardiovascular Genetics | December 2, 2014 | Volume: 8 | Issue: 1 | Pages: 141-149

10.1161/circgenetics.114.000624 | PMID 25452597 Get It

Background— The goal of this study was to identify genetic determinants of plasma N-terminal proatrial natriuretic peptide (NT-proANP) in the general community by performing a large-scale genetic association study and to assess its functional significance in in vitro cell studies and on disease susceptibility. Methods and Results— Genotyping was performed across 16 000 genes in 893 randomly selected individuals, with replication in 891 subjects from the community. Plasma NT-proANP 1–98 concentrations were determined using a radioimmunoassay. Thirty-three genome-wide significant single-nucleotide polymorphisms were identified in the MTHFR-CLCN6-NPPA-NPPB locus and were all replicated. To assess the significance, in vitro functional genomic studies and clinical outcomes for carriers of a single-nucleotide polymorphism rs5063 (V32M) located in NPPA that represented the most significant variation in this genetic locus were assessed. The rs5063 variant allozyme in transfected HEK293 cells was decreased to 55±8% of wild-type protein ( P =0.01) as assessed by quantitative western blots. Carriers of rs5063 had lower NT-proANP levels (1427 versus 2291 pmol/L; P <0.001) and higher diastolic blood pressures (75 versus 73 mm Hg; P =0.009) and were at an increased risk of stroke when compared with wild-type subjects independent of age, sex, diabetes mellitus, hypertension, atrial fibrillation, and cholesterol levels (hazard ratio, 1.6; P =0.004). Conclusions— This is the first large-scale genetic association study of circulating NT-proANP levels performed with replication and functional assessment that identified genetic variants in the MTHFR-CLCN6-NPPA-NPPB cluster to be significantly associated with NT-proANP levels. The clinical significance of this variation is related to lower NT-proANP levels, higher blood pressures, and an increased risk of stroke in the general community.
Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
Hart, Steven N. , Sharma, Priyanka , Miron, Penelope , Olswold, Curtis, Slettedahl, Seth W. , Hallberg, Emily, Guidugli, Lucia, Davila, Jaime , Beckmann, Matthias W. , Janni, Wolfgang , Rack, Brigitte , Ekici, Arif B. , Slamon, Dennis J. , Konstantopoulou, Irene , Vratimos, Athanassios, Fountzilas, George , Pelttari, Liisa M. , Tapper, William , Durcan, Lorraine , Cross, Simon S. , Pilarski, Robert , Klemp, Jennifer R. , Cox, Angela , Brauch, Hiltrud , Yannoukakos, Drakoulis , Slager, Susan L., Vachon, Celine M. , Eccles, Diana M., Fasching, Peter A. , Eccles, Diana , Wang, Xianshu , Slettedahl, Seth, Davila, Jaime I, Tapper, William J, Shapiro, Charles L. , Klemp, Jennifer, Garber, Judy, Ambrosone, Christine, Couch, Fergus J. , Toland, Amanda Ewart , Olson, Janet E. , Godwin, Andrew K. , Pankratz, V. Shane , Fostira, Florentia , Yao, Song , Garber, Judy E. , Ambrosone, Christine B. , Nevanlinna, Heli , Vachon, Celine M. , Eccles, Diana M., Fasching, Peter A , Pelttari, L M , Eccles, Diana , Konstantopoulou, Irene , Slettedahl, Seth W , Hart, Steven N , Cox, Angela , Ekici, Arif B , Davila, Jaime I , Yannoukakos, Drakoulis , Sharma, Priyanka , Brauch, Hiltrud

Journal of Clinical Oncology | December 2, 2014 | Volume: 33 | Issue: 4 | Pages: 304-311

10.1200/jco.2014.57.1414 | PMID 25452441 Get It

Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing of patients. We assessed the frequency of mutations in 17 predisposition genes, including BRCA1 and BRCA2, in a large cohort of patients with triple-negative breast cancer (TNBC) unselected for family history of breast or ovarian cancer to determine the utility of germline genetic testing for those with TNBC. Patients and Methods Patients with TNBC (N = 1,824) unselected for family history of breast or ovarian cancer were recruited through 12 studies, and germline DNA was sequenced to identify mutations. Results Deleterious mutations were identified in 14.6% of all patients. Of these, 11.2% had mutations in the BRCA1 (8.5%) and BRCA2 (2.7%) genes. Deleterious mutations in 15 other predisposition genes were detected in 3.7% of patients, with the majority observed in genes involved in homologous recombination, including PALB2 (1.2%) and BARD1, RAD51D, RAD51C, and BRIP1 (0.3% to 0.5%). Patients with TNBC with mutations were diagnosed at an earlier age (P < .001) and had higher-grade tumors (P = .01) than those without mutations. Conclusion Deleterious mutations in predisposition genes are present at high frequency in patients with TNBC unselected for family history of cancer. Mutation prevalence estimates suggest that patients with TNBC, regardless of age at diagnosis or family history of cancer, should be considered for germline genetic testing of BRCA1 and BRCA2. Although mutations in other predisposition genes are observed among patients with TNBC, better cancer risk estimates are needed before these mutations are used for clinical risk assessment in relatives.
Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy
Hijazi, Ziad , Siegbahn, Agneta , Andersson, Ulrika , Granger, Christopher B. , Alexander, John H. , Hanna, Michael , Harjola, Veli‐Pekka , Horowitz, John D. , McMurray, John J.V. , Wallentin, Lars , Hanna, Michael G. , Lindahl, Bertil , Atar, Dan , Gersh, Bernard J. , Husted, Steen , Hylek, Elaine M. , Lópes, Renato D. , McMurray, John J V , Granger, Christopher B

Clinical Chemistry | December 2, 2014 | Volume: 61 | Issue: 2 | Pages: 368-378

10.1373/clinchem.2014.226936 | PMID 25451868 Get It

Abstract BACKGROUND Although cardiac troponin is associated with outcomes in atrial fibrillation (AF), the complementary prognostic information provided by cardiac troponin I (cTnI) and cTnT is unknown. This study investigated the distribution, determinants, and prognostic value of cTnI and cTnT concentrations in patients with AF. METHODS Samples were collected. At the time of randomization, we analyzed cTnI and cTnT concentrations of 14806 AF patients in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial using high-sensitivity assays. Correlations (Spearman), determinants (multivariable linear regression), and outcomes (adjusted Cox models and c-statistics) were investigated. RESULTS Concentrations of cTnI and cTnT were correlated (r = 0.70) and measurable in most participants [cTnI 98.5% (median 5.4 ng/L, ≥99th percentile in 9.2%) and cTnT 93.5% (median 10.9 ng/L, ≥99th percentile in 34.4%)]. Renal impairment was the most important factor affecting the concentrations of both troponins. cTnI increase was more associated with heart failure, vascular disease, and persistent/permanent AF, and cTnT with age, male sex, and diabetes. Over a median 1.9 years of follow-up, patients with both troponins above the median had significantly higher risk for stroke/systemic embolism [hazard ratio (HR) 1.72 (95% CI 1.31–2.27)], cardiac death [3.14 (2.35–4.20)], and myocardial infarction [2.99 (1.78–5.03)] than those with both troponins below median (all P &lt; 0.005). Intermediate risks were observed when only 1 troponin was above the median. When combined with clinical information, each marker provided similar prognostication and had comparable c-index. CONCLUSIONS cTnI and cTnT concentrations are moderately correlated and measurable in plasma of most AF patients. The risk of stroke and cardiovascular events is highest when both troponins are above median concentrations. Each troponin provides comparable prognostic information when combined with clinical risk factors. ClinicalTrials.gov/NCT00412984